Evotec, Bristol Myers Squibb, and Sandoz announced the evolution of their strategic partnership and financial results from Hamburg.
3 reports, 1 independent
Updated Aug 13
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Evotec, Bristol Myers Squibb, and Sandoz announced the evolution of their strategic partnership and financial results from Hamburg.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Evotec successfully lists on Nasdaq and validates its model through a transaction with Sandoz, building on its partnership with Sandoz.Sub-event
- Sandoz and Evotec announced a strategic partnership and potential sale of the Just - Evotec Biologics EU site in Toulouse.Sub-event
Strategic partnership between Evotec, BMS, and Sandoz evolves, focusing on targeted protein degradation.1 source
Keep exploring
The entities involved
-
Sandoz
organization
Nothing else this week.
-
Evotec
company
Nothing else this week.
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- ACCESS NewswireEvotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions
- ACCESS NewswireEvotec SE to announce first half-year results 2025 on 13 August 2025 HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE000
- ACCESS NewswireEvotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix Successful execution of new strategy for sustainable and profitable growth leading to changing